China Aflibercept Market Investigation Report 2022-2031 – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Investigation Report on China's Aflibercept Market 2022-2031" report has been added to ResearchAndMarkets.com's offering. Aflibercept is an anti-VEGF drug, mainly used to treat neovascular age-related macular degeneration (wAMD), and other retinopathy caused by visual impairment. Aflibercept was jointly developed by Regeneron and Bayer. Regeneron has exclusive sales rights in the U.S. market, while Bayer obtains exclusive sales rights outside the U.S. Their Afliber